TS-005532 — This treatment of SLC35A2 (Solute Carrier Family 35 Member A2) genetic disorders uses AAV (Adeno-Associated Viral Vectors) vectors to restore gene function. Mutation in the SLC35A2 gene is often linked to a severe metabolic condition characterized by early-onset epilepsy, developmental delay, and intellectual disability. Applications include a SLC35A2 gene replacement as a therapy for SLC35A2 related epilepsy and congenital disorder of glycosylation.